Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-08-16
2008-12-30
Marschel, Ardin (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S356000
Reexamination Certificate
active
07470718
ABSTRACT:
Methods for treating a demyelinating condition in a subject in need of treatment are provided. In some aspects the methods encompass administering to the subject an amount of a Ca2+-channel blocker effective to treat the demyelinating condition. In other aspects, the methods encompass administering to the subject an amount of a glutamate inhibitor effective to treat the demyelinating condition. In additional aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a glutamate inhibitor, in amounts effective to treat the demyelinating condition. In still other aspects, the methods encompass administering to the subject a Ca2+-channel blocker in combination with a hypertensive agent, in amounts effective to treat the demyelinating condition. Also provided are pharmaceutical compositions having a Ca2+-channel blocker, a glutamate inhibitor, and a pharmaceutically-acceptable carrier. Additionally, pharmaceutical compositions having a Ca2+-channel blocker, a hypertensive agent, and a pharmaceutically-acceptable carrier are provided.
REFERENCES:
patent: 5990103 (1999-11-01), Schonharting et al.
patent: 6187756 (2001-02-01), Lee et al.
patent: 6190691 (2001-02-01), Mak
patent: 6277850 (2001-08-01), Lubisch et al.
patent: 6337325 (2002-01-01), Schonharting et al.
patent: 6531464 (2003-03-01), Szabo et al.
patent: WO 92/07564 (1992-05-01), None
patent: WO 00/01376 (2000-01-01), None
patent: WO 01/87280 (2001-11-01), None
Medline An 95354533, Ditzen et al, Deutsche Medizinische Wochenschrift, Jul. 28, 1995, 120 (30) 1061-2, abstract.
Ditzen et al, Deutsche medizinishche wochenscrift, Jul. 18, 1995, 120(30) 1061-2 and translated document.
Akassoglou, K., et al, Oligodendrocyte Apoptosis and Primary Demyelination Induced by Local TNF/p55TNF Receptor Signaling in the Central Nervous System of Transgenic Mice, American Journal of Pathology, 153:801-813 (1998).
Canella, B., et al, The neuregulin, glial growth factor 2, diminishes autoimmune demyelination and enhances remyelination in a chronic relapsing model for multiple sclerosis, Proc. Natl. Acad. Sci. USA, 95:10100-10105 (1998).
Mason, R.P., et al, Inhibition of Excessive Neuronal Apoptosis by the Calcium Antagonist Amlodipine and Antioxidants in Cerebellar Granule Cells, Journal of Neurochemistry, 72:1448-1456 (1999).
McDonald, J. W., et al, Oligodendrocytes from forebrain are highly vulnerable to AMPA/kainate receptor-mediated excitotoxicity, Nat. Med., 4:291-297 (1998).
Piani, D., et al, Murine brain macrophages induced NMDA receptor mediated neurotoxicity in vitro by secreting glutamate, Neurosci. Lett., 133:159-162 (1991).
Pitt, D., et al, Glutamate excitotoxicity in a model of multiple sclerosis, Nat. Med., 6:67-70 (2000).
Rayner, D.C., et al, Major histocompatability complex class II-restricted cytotoxicity by self-myelin basic protein-reactive T-cell hybridomas: evidence for a tumour necrosis factor-independent nucleolytic mechanism, Immunology, 78:273-278 (1993).
Waxman, S.G., et al, Protection of the axonal cytoskeleton in anoxic optic nerve by decreased extracellular calcium, Brain Res., 614:137-145 (1993).
Werner, P., et al, Glutamate excitotoxicity—a mechanism for axonal damage and oligodendrocyte death in Multiple Sclerosis?, J. Neural Transm. Suppl., 60:375-385 (2000).
Brand-Schieber, E. et al., Ca2+ Blockers Ameliorate Disease In Mouse Model of Multiple Sclerosis (MS), J. Neurochemistry, 81:50 (Jun. 22, 2002).
Brosnan and Raine, Mechanisms of Immune Injury in Multiple Sclerosis. Brain Pathology. vol. 6. pp. 243-257 (1996).
El-Fawal H.A.N. et al., Effect of Verapamil on Organophosphorus—Induced Delayed Neuropathy in Hens. Toxicology and Applied Pharmacology. vol. 97. pp. 500-511 (1989).
Flanagan E.M. et al., Neurotoxin Quinolinic Acid Is Selectively Elevated in Spinal Cords of Rats with Experimental Allergic Encephalomyelitis. Journal of Neurochemistry. vol. 64. No. 3. pp. 1192-1196 (1995).
Gilmore R.L. et al., Verapamii-induced changes conduction in patients with multiple sclerosis. Journal of Neurology, Neurosurgery, and Psychiatry. vol. 48. pp. 1140-1146 (1985).
Hartai Z. et al., Kynurenine metabolism in multiple sclerosis. Acta Neurologica Scandinavica. vol. 112. pp. 93-96 (2005).
Komoly S. et al. Multiple sclerosis: failure of treatment with verapamil in a pilot trial. Journal of Neurology. vol. 233. pp. 59-60 (1986).
Kozlovskii V.L. et al. Anticalcium preparations that prevent the neurodegenerative action of quinolinic acid. Farmakol. Toksikol. vol. 53. No. 2. pp. 27-29 (1990). [Abstract].
Martin and McFarland, Immunology of Multiple Sclerosis and Experimental Allergic Encephalomyelitis. Chapter 14 in “Multiple Sclerosis: Clinical and Pathogenetic Basis” Ed. Cedric S. Raine et al., Chapman & Hall, London 1997.
Oleszak E.L. et al., Theiler's Virus Infection: a Model for Multiple Sclerosis. Clinical Microbiology Reviews. vol. 17. No. 1. pp. 174-207 (2004).
Reinhard Jr. J.F. et al., Quinolinic Acid in Neurological Disease: Opportunities for Novel Drug Discovery. Advances in Pharmacology. vol. 30. pp. 85-127. (1994).
Yanagisawa K. et al., Degradation of Myelin Basic Protein by Calcium-Activated Neutral Protease (CANP) in Human Brain and Inhibition by E-64 Analogue. Neurochemical Research. vol. 8. No. 10. pp. 1285-1293 (1983).
Brand-Schieber Elimor
Pitt David
Werner Peter
Albert Einstein College of Medicine of Yeshiva University
Amster Rothstein & Ebenstein LLP
Anderson James D
Marschel Ardin
LandOfFree
Method for treating a demyelinating condition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for treating a demyelinating condition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for treating a demyelinating condition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4045694